A Rising Yen Leads Japan Into a Tricky Balancing Act

Marketing

AMSTERDAM (Reuters) - US diversified health care company Johnson & Johnson has bought an 18 percent stake in biotech firm Crucell for 302 million euros ($444 million) as part of a flu vaccine development deal, the Dutch company said ...

Crucell CEO: Now Is A Good Time For Acquisitions Wall Street Journal

Johnson & Johnson buys 18 percent stake in Crucell The Associated Press

Forbes - FierceBiotech - MarketWatch

Post je objavljen 28.09.2009. u 15:26 sati.

Pregled posta

Marketing

A Rising Yen Leads Japan Into a Tricky Balancing Act